Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
WEIGHT-GAIN ASSOCIATED WITH NEUROLEPTIC MEDICATION - A REVIEW
Autore:
STANTON JM;
Indirizzi:
AUCKLAND HOSP,EATING DISORDERS SERV,PRIVATE BAG 92024 AUCKLAND NEW ZEALAND
Titolo Testata:
Schizophrenia bulletin
fascicolo: 3, volume: 21, anno: 1995,
pagine: 463 - 472
SICI:
0586-7614(1995)21:3<463:WAWNM->2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
ENERGY-INTAKE; SCHIZOPHRENIC-PATIENTS; PSYCHOTROPIC-DRUGS; ADIPOSE-TISSUE; CARDIOVASCULAR-DISEASE; HALOPERIDOL DECANOATE; DENOVO LIPOGENESIS; NEGATIVE SYMPTOMS; COMPARATIVE TRIAL; DIET-COMPOSITION;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Physical, Chemical & Earth Sciences
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
93
Recensione:
Indirizzi per estratti:
Citazione:
J.M. Stanton, "WEIGHT-GAIN ASSOCIATED WITH NEUROLEPTIC MEDICATION - A REVIEW", Schizophrenia bulletin, 21(3), 1995, pp. 463-472

Abstract

In this article we review the empirical literature on weight gain associated with neuroleptic drug use. Weight gain, which appears to be associated with an increase in appetite, is variable but likely to be larger initially and then plateau. Clozapine and low-potency phenothiazines are associated with the largest gains and molindone with weight loss, but the mechanism is not known. Amantadine and fenfluramine may reverse weight gain to some degree. Dietary fat seems to play an important role in obesity, and research is needed to increase the data base and elucidate possible mechanisms. Studies are also needed to evaluate preventive strategies and to determine which drugs are least likely toproduce weight gain as well as which drugs could be added to a neuroleptic regimen to control weight.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/09/20 alle ore 05:22:13